CYNATA THERAPEUTICS LIMITED

2.63%

19.5¢

Market Cap $46.30M

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

Recce Pharmaceuticals (ASX:RCE) eyes US Defence grants with early data for R327 on burn wounds

Latest Threads

Tag

Subject

CYP

Cynata Enters Countdown to Landmark Clinical Results as World-First MSC Platform Advances

21:52

466

21:52

Last post Pledge

466

CYP

"Good vibes Here Dudes".....

2 3

09/09/25

153

52K

09/09/25

Last post Pledge

153

52K

CYP Biotech

CYP Price Target post MSB FDA approval.

5 6 7

06/09/25

392

117K

06/09/25

Last post Pledge

392

117K

CYP

Ann: Corporate Governance Statement

30/08/25

276

30/08/25

Last post Pledge

276

CYP

Ann: Appendix 4G

28/08/25

153

28/08/25

Last post

ASX News

153

CYP

Ann: Appendix 4E & Annual Report

28/08/25

228

28/08/25

Last post

ASX News

228

CYP

Ann: Cynata to present at Bioshares Biotech Summit

27/08/25

1.1K

27/08/25

Last post Pledge

1.1K

CYP

Ann: At-the-Market Subscription Agreement

27/08/25

5.1K

27/08/25

Last post bedger

5.1K

See All Discussions

Timeline

Appendix 4G
28 Aug 18:24	Share

Corporate Governance Statement
28 Aug 18:23	Share

Appendix 4E & Annual Report
28 Aug 18:23	Share

Change in substantial holding
26 Aug 18:23	Share

Cleansing Notice
22 Aug 09:18	Share

Application for quotation of securities - CYP
22 Aug 09:18	Share

At-the-Market Subscription Agreement
22 Aug 09:17	Share

Cynata to present at Bioshares Biotech Summit
07 Aug 08:46	Share

Investor Webinar
05 Aug 08:32	Share

June 2025 Quarterly Activity Report and Appendix 4C
30 Jul 09:45	Share

Notification regarding unquoted securities - CYP
10 Jun 15:57	Share

Proposed issue of securities - CYP
04 Jun 08:24	Share

InvestorHub Portal and New Website
22 May 08:43	Share

CYP-001s FDA Approval Pathway Not Impeded
16 May 12:12	Share

Investor Webinar
05 May 08:28	Share

March 2025 Quarterly Activity Report and Appendix 4C
24 Apr 13:12	Share

Australian Federal Government Announces Funding of SMART CRC
24 Apr 11:48	Share

Cynata Establishes New Scientific Advisory Board
14 Apr 08:45	Share

Promising Preclinical Heart Disease Data
07 Apr 08:46	Share

Appendix 3Ys x 4
01 Apr 18:00	Share

Cynata Presenting at Advanced Therapies Congress
18 Mar 08:50	Share

Cynata Participating in Euroz Hartleys Investor Conference
12 Mar 08:53	Share

Appendix 4D & Half-Year Financial Statements
27 Feb 15:04	Share

Expiry of listed CYPOA Options
27 Feb 11:58	Share

Appendix 3Y - Paul Wotton
20 Feb 15:22	Share

Application for quotation of securities - CYP
20 Feb 15:17	Share

Investor Webinar
06 Feb 08:56	Share

Publication comparing Cymerus MSCs to other MSCs
05 Feb 09:12	Share

Cynata to Present at Euroz Hartleys Healthcare Forum
04 Feb 08:37	Share

Quarterly Activity Report & Appendix 4C
30 Jan 08:52	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 19.5¢		Change 0.005(2.63%)		Mkt cap ! $46.30M

Open	High	Low	Value	Volume
19.0¢	19.5¢	18.0¢	$53.29K	289.3K

Buyers (Bids)

No.	Vol.	Price($)
1	83333	19.0¢

Sellers (Offers)

Price($)	Vol.	No.
19.5¢	4869	2

View Market Depth

No.	Vol.	Price($)
1	83333	0.190
2	91560	0.180
4	135266	0.175
5	172143	0.170
3	85000	0.160

Price($)	Vol.	No.
0.195	4869	2
0.200	90959	1
0.205	184639	1
0.210	1202	1
0.215	10000	1

Last trade - 15.02pm 11/09/2025 (20 minute delay)


Last 19.0¢		Change 0.005 ( 0.00 %)
Open	High	Low	Volume
18.5¢	19.0¢	18.0¢	184584
Last updated 11.10am 11/09/2025 ?

CYP (ASX) Chart

CYNATA THERAPEUTICS LIMITED

Latest Threads

Two '4D' stocks to watch, but only one winner

Timeline

Featured News

Latest Videos

Cynata Therapeutics (ASX:CYP) receives approval for acute graft-versus-host disease clinical trial

30 Jan 2023 14:49 (AEDT)

Latest Articles

Cynata's stem cell tech verified in peer-reviewed study

Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified as similar to convention MSCs in a study published in a peer-review journal.

Cynata study shows efficacy of stem-cell therapy on chronic lung disease

Cynata Therapeutics Ltd has published a study examining the effect of its Cymerus therapy on idiopathic pulmonary fibrosis symptoms.

Cynata wins EU ethics approval for phase 2 Trial of CYP-001

Cynata Therapeutics has been given EU regulatory and ethics approval for phase 2 Trial of its latest development 'CYP-001'

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News